XRAY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
DENTSPLY SIRONA Inc (XRAY) is not a strong buy at the moment for a beginner investor with a long-term focus. While the company has shown some positive revenue growth and analysts have upgraded their ratings, significant financial challenges, negative technical indicators, and the elimination of dividends make it less attractive for immediate investment. Holding off for clearer signs of recovery or stability is recommended.
The technical indicators suggest a bearish trend. The MACD is negatively expanding, RSI is neutral at 46.999, and moving averages indicate a bearish alignment (SMA_200 > SMA_20 > SMA_5). The stock is trading near its resistance level of 13.475, with key support at 12.268.
Revenue increased by 6.2% YoY in Q4
Analysts have recently upgraded the stock, with BofA raising its price target to $17 and upgrading to Buy.
The company is implementing a 'Return to Growth' plan, which could stabilize performance over the medium term.
Net income dropped significantly by 66.05% YoY, and EPS fell by 66.20% YoY in Q4
Gross margin decreased by 8.31% YoY.
The dividend has been eliminated, which may deter income-focused investors.
Ongoing investigation by Halper Sadeh LLC into potential fiduciary breaches could weigh on sentiment.
Bearish technical indicators and lack of strong upward momentum.
In Q4 2025, revenue increased by 6.19% YoY to $961 million. However, net income dropped to -$146 million (-66.05% YoY), and EPS fell to -$0.73 (-66.20% YoY). Gross margin also declined to 46.1% (-8.31% YoY), indicating financial challenges despite revenue growth.
Analysts have mixed views but lean positive recently. BofA upgraded the stock to Buy with a price target of $17, citing a positive risk/reward outlook. UBS maintains a Buy rating but lowered its price target to $16. Mizuho raised its target to $14 with a Neutral rating, while Barclays initiated coverage with an Underweight rating and a $12 target.
